MarketPeel
Insider Trading Intelligence
Pricing
…
RS

Rajeev Saggar

LQDA
CHIEF MEDICAL OFFICER · LIQUIDIA CORP · CIK 0001935638
FILING MIX · LIFETIME38%/62%
BUYS
20
SELLS
33
TOTAL VALUE
$6.55M
COMPANIES
1
ACTIVE SINCE
Jul 2022
HOLDINGS NOW
171,799
AVG SELL PX
$29.05
TRADE KIND
SHOWING 53 / 53
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
23 backtested trades · 8 horizons · 27 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Rajeev Saggar, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d23+43.48%+4.65%+0.44%+4.21%+1.39%—
14d23+56.52%+6.63%+0.69%+5.95%+0.72%—
30d23+43.48%+16.49%+2.65%+13.83%+10.21%—
60d23+43.48%+17.30%+4.12%+13.18%+4.77%—
90d23+30.43%+30.01%+5.34%+24.66%+10.77%—
180d23(2 pending)+28.57%+41.10%+9.10%+32.00%+32.31%—
1y23(8 pending)+26.67%+117.34%+17.04%+91.98%+54.84%—
2y23(17 pending)+16.67%+251.02%+36.92%+214.10%+140.24%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
LQDA · 171,799 shares · as of Jul 13, 2026
070,202140,403210,605280,8062023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
2026
FLOW · 20 buys / 33 sellsCOVERAGE · 17 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
9,223$71.52$659.6K171,799Jul 13, 2026Jul 14, 2026 ↗View →
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
703$71.39$50.2K181,022Jul 13, 2026Jul 14, 2026 ↗View →
LQDA
LIQUIDIA CORP
PURCHASE
Chief Medical Officer
4,487——181,725Jul 10, 2026Jul 14, 2026 ↗View →
LQDA
LIQUIDIA CORP
SALE
Chief Medical Officer
3,531——21,184Jul 10, 2026Jul 14, 2026 ↗View →
LQDA
LIQUIDIA CORP
SALE
Chief Medical Officer
4,487——44,862Jul 10, 2026Jul 14, 2026 ↗View →
LQDA
LIQUIDIA CORP
PURCHASE
Chief Medical Officer
3,531——177,238Jul 10, 2026Jul 14, 2026 ↗View →
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
9,220$38.37$353.8K173,270Apr 13, 2026Apr 14, 2026 ↗View →
LQDA
LIQUIDIA CORP
SALE
Chief Medical Officer
3,531——24,715Apr 10, 2026Apr 14, 2026 ↗View →
LQDA
LIQUIDIA CORP
PURCHASE
Chief Medical Officer
4,486——182,490Apr 10, 2026Apr 14, 2026 ↗View →
LQDA
LIQUIDIA CORP
PURCHASE
Chief Medical Officer
3,531——178,004Apr 10, 2026Apr 14, 2026 ↗View →
LQDA
LIQUIDIA CORP
SALE
Chief Medical Officer
4,486——49,349Apr 10, 2026Apr 14, 2026 ↗View →
LQDA
LIQUIDIA CORP
SALE
Chief Medical Officer
35,365$36.30$1.28M174,473Mar 13, 2026Mar 17, 2026 ↗View →
LQDA
LIQUIDIA CORP
PURCHASEGRANT
Stock grant
32,955——209,838Jan 16, 2026Jan 21, 2026 ↗View →
LQDA
LIQUIDIA CORP
PURCHASEGRANT
Stock grant
49,433——49,433Jan 16, 2026Jan 21, 2026 ↗View →
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
21,142$37.43$791.3K176,883Jan 12, 2026Jan 13, 2026 ↗View →
LQDA
LIQUIDIA CORP
PURCHASE
Chief Medical Officer
17,945——198,025Jan 9, 2026Jan 13, 2026 ↗View →
LQDA
LIQUIDIA CORP
SALE
Chief Medical Officer
17,945——53,835Jan 9, 2026Jan 13, 2026 ↗View →
LQDA
LIQUIDIA CORP
SALE
Chief Medical Officer
3,531——28,246Jan 9, 2026Jan 13, 2026 ↗View →
LQDA
LIQUIDIA CORP
PURCHASE
Chief Medical Officer
3,531——180,080Jan 9, 2026Jan 13, 2026 ↗View →
LQDA
LIQUIDIA CORP
SALE
Chief Medical Officer
66,463$27.00$1.79M176,549Nov 5, 2025Nov 7, 2025 ↗View →
LQDA
LIQUIDIA CORP
SALE
Chief Medical Officer
4,918$27.00$132.8K243,012Nov 5, 2025Nov 7, 2025 ↗View →
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
5,327$23.41$124.7K247,930Oct 13, 2025Oct 15, 2025 ↗View →
LQDA
LIQUIDIA CORP
PURCHASE
Chief Medical Officer
3,530——253,257Oct 10, 2025Oct 15, 2025 ↗View →
LQDA
LIQUIDIA CORP
SALE
Chief Medical Officer
3,530——31,777Oct 10, 2025Oct 15, 2025 ↗View →
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
20,000$27.85$557.1K249,727Aug 28, 2025Sep 2, 2025 ↗View →
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
2,526$14.54$36.7K268,887Jul 21, 2025Jul 23, 2025 ↗View →
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
5,327$14.28$76.1K271,413Jul 14, 2025Jul 15, 2025 ↗View →
LQDA
LIQUIDIA CORP
SALE
Chief Medical Officer
3,531——35,307Jul 11, 2025Jul 15, 2025 ↗View →
LQDA
LIQUIDIA CORP
PURCHASE
Chief Medical Officer
3,531——276,740Jul 11, 2025Jul 15, 2025 ↗View →
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
7,597$16.97$128.9K273,209Jun 4, 2025Jun 5, 2025 ↗View →
LQDA
LIQUIDIA CORP
SALE
Chief Medical Officer
17,654——38,838Jun 3, 2025Jun 5, 2025 ↗View →
LQDA
LIQUIDIA CORP
PURCHASE
Chief Medical Officer
17,654——280,806Jun 3, 2025Jun 5, 2025 ↗View →
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
2,450$13.67$33.5K263,152Apr 21, 2025Apr 23, 2025 ↗View →
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
3,714$13.57$50.4K265,602Apr 14, 2025Apr 16, 2025 ↗View →
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
2,445$13.00$31.8K267,943Jan 21, 2025Jan 23, 2025 ↗View →
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
6,249$11.78$73.6K270,388Jan 14, 2025Jan 14, 2025 ↗View →
LQDA
LIQUIDIA CORP
PURCHASEGRANT
Stock grant
71,780——71,780Jan 11, 2025Jan 14, 2025 ↗View →
LQDA
LIQUIDIA CORP
PURCHASEGRANT
Stock grant
71,780——276,637Jan 11, 2025Jan 14, 2025 ↗View →
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
2,526$11.19$28.3K204,857Oct 18, 2024Oct 22, 2024 ↗View →
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
2,260$11.11$25.1K207,383Oct 14, 2024Oct 15, 2024 ↗View →
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
1,873$11.13$20.8K208,329Jul 19, 2024Jul 22, 2024 ↗View →
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
1,470$12.53$18.4K210,202Jul 12, 2024Jul 15, 2024 ↗View →
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
1,649$13.68$22.6K211,672Apr 19, 2024Apr 23, 2024 ↗View →
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
1,525$14.58$22.2K213,321Apr 12, 2024Apr 16, 2024 ↗View →
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
5,876$15.82$93.0K214,846Mar 18, 2024Mar 19, 2024 ↗View →
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
1,654$15.82$26.2K220,722Mar 18, 2024Mar 19, 2024 ↗View →
LQDA
LIQUIDIA CORP
PURCHASEGRANT
Stock grant
56,492——220,591Jan 11, 2024Jan 16, 2024 ↗View →
LQDA
LIQUIDIA CORP
PURCHASEGRANT
Stock grant
56,492——56,492Jan 11, 2024Jan 16, 2024 ↗View →
LQDA
LIQUIDIA CORP
PURCHASE
Chief Medical Officer
14,887$7.42$110.5K164,099Dec 18, 2023Dec 19, 2023 ↗View →
LQDA
LIQUIDIA CORP
PURCHASEGRANT
Stock grant
106,838——106,838Jan 11, 2023Jan 13, 2023 ↗View →
LQDA
LIQUIDIA CORP
PURCHASEGRANT
Stock grant
83,333——177,167Jan 11, 2023Jan 13, 2023 ↗View →
LQDA
LIQUIDIA CORP
PURCHASEGRANT
Stock grant
93,834——93,834Jul 18, 2022Jul 20, 2022 ↗View →
LQDA
LIQUIDIA CORP
PURCHASEGRANT
Stock grant
200,000——200,000Jul 18, 2022Jul 20, 2022 ↗View →
Other insiders · LQDA
Loading peer insiders…
About this filer
CIK 0001935638
ROLE
Chief Medical Officer
PRIMARY
LQDA
COMPANIES
1
ACTIVE SINCE
Jul 2022
MARKETPEEL · /INSIDER/0001935638DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback